Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Structure-Based Discovery of Potent BCL-XL Inhibitors through Rescaffolding.

Journal of medicinal chemistry·2026
Same author

A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.

Leukemia·2026
Same author

Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS.

Cell reports. Medicine·2026
Same author

Isolation of a single Serratia fonticola strain from interstage samples in a drinking water treatment plant: Genomic insights and floc-shielding effects during chlorination.

Ecotoxicology and environmental safety·2026
Same author

Exploiting a Cryptic Pocket in DsbA through Structure-Guided Parallel Synthesis and Direct-to-Biology Screening.

Journal of medicinal chemistry·2026
Same author

Targeting PTPN22 at Nonorthosteric Binding SitesA Fragment Approach.

ACS omega·2026

相关实验视频

Updated: Apr 30, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

选择性USP7抑制剂的结构导向发现具有体外活性.

Attila Vasas1, Lisa Ivanschitz2, Balázs Molnár1

  • 1Servier Research Institute of Medicinal Chemistry, Záhony u. 7., Budapest H-1031, Hungary.

Journal of medicinal chemistry
|October 23, 2024
PubMed
概括

研究人员优化了一种向无素特定蛋白酶7 (USP7) 的化合物,该蛋白质是癌症中的关键蛋白质. 改进的化合物实现了高亲和力,证明了瘤的向参与,并在临床前癌症模型中显示出有效性.

更多相关视频

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

233

相关实验视频

Last Updated: Apr 30, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

233

科学领域:

  • 生物化学 生物化学
  • 药用化学 医学化学
  • 在瘤学瘤学.

背景情况:

  • 乌比奎丁特异性蛋白酶7 (USP7) 是瘤学中已验证的标.
  • 基于结构的药物设计对于优化小分子抑制剂至关重要.

研究的目的:

  • 优化低微分子USP7抑制剂,以达到高亲和度和体内疗效.
  • 探索结构-活动关系围绕一个定义不佳的USP7.7的绑定口袋.

主要方法:

  • 结构导向药物设计使用USP7抑制剂的晶体结构.
  • 复合库的高通量选,以识别最初的命中.
  • 系统的化学修饰和选替代剂以提高亲和力.
  • 在体内研究,包括异种移植模型中的目标参与,耐受性和疗效.

主要成果:

  • 抑制剂的一个区域的优化导致了结合亲和力的显著增加.
  • 优化的化合物实现了对USP7.7的低纳米系亲和力.
  • 化合物在瘤中表现出向参与,并且在小鼠中耐受良好.
  • 在临床前的异种移植癌症模型中观察到显著的疗效.

结论:

  • 结构引导优化USP7抑制剂可以产生强效的药物候选者.
  • 针对USP7代表了对各种癌症的有希望的治疗策略.
  • 开发的化合物显示出在瘤学领域进一步临床开发的潜力.